William Blair Thinks Travere Therapeutics’ Stock is Going to Recover
William Blair analyst Tim Lugo maintained a Buy rating on Travere Therapeutics (TVTX) on May 26. The company’s shares closed last Friday at $15.23, close to its 52-week low of $14.43.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 17.6% and a 48.9% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and VistaGen Therapeutics.
Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.14, a 106.4% upside from current levels. In a report issued on May 14, Canaccord Genuity also maintained a Buy rating on the stock with a $48.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.09 and a one-year low of $14.43. Currently, Travere Therapeutics has an average volume of 596.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.